RxDoctor Payments Data

Victorine Yangni

Family · Houston, TXNPI 1689113177

Payments from drug & device makers

$734in general payments, 2019–2025

Across 46 payments — averaging $15.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amarin Pharma, Inc.$140
  • Teva Pharmaceuticals USA, Inc.$119
  • Sumitomo Pharma America, Inc.$95
  • Novartis$50
  • Redhill Biopharma Inc.$45
  • Sunovion Pharmaceuticals Inc.$43
  • plus $241 from 11 others

What the payments were for

  • Food & beverage$734100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$734 in reported general payments places this provider in the 60th percentile of 15,456 family providers in Texas.

See all family providers in Texas

Medicare billing

Part B allowed, 2024
$12,082
Medicare patients
70
Services billed
136

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide62$73,424
VascepaIcosapent Ethyl90$35,960
TrulicityDulaglutide24$23,560
MounjaroTirzepatide15$15,678
EliquisApixaban25$14,232
EntrestoSacubitril/Valsartan18$12,367
JardianceEmpagliflozin13$12,216
TradjentaLinagliptin13$6,748
Mometasone Furoate51$5,532
Lidocaine34$3,743
Metformin Er GastricMetformin Hcl19$3,595
Diclofenac Sodium81$3,321
Icosapent Ethyl14$3,135
Clonidine13$1,716
Lantus SolostarInsulin Glargine,hum.Rec.Anlog12$1,299

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$35$39,23839 claims
NovartisEntresto$50$12,36718 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 15,456 family providers in Texas.

Other family in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →